Premium
Danazol therapy in hormone‐sensitive mammary carcinoma
Author(s) -
Peters Thomas G.,
Lewis J. David,
Wilkinson Edward J.,
Fuhrman Thomas M.
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197712)40:6<2797::aid-cncr2820400607>3.0.co;2-9
Subject(s) - danazol , medicine , dmba , mammary carcinoma , cancer , breast cancer , hormone , mammary gland , oncology , carcinoma , mammary tumor , endocrinology , carcinogenesis , endometriosis
The effect of Danazol, a synthetic gonadotropin inhibitor, on two groups of Sprague‐Dawley rats with dimethylbenze (a) anthracine (DMBA) induced mammary carcinoma was studied. Twenty‐four (83%) of 29 control animals developed mammary tumors. Forty‐four rats in one treatment group received Danazol after tumor reached 0.5 cm in diameter. Twenty‐nine (66%) demonstrated tumor regression (p < 0.0005) and in 16 (36%) tumor disappeared (p < 0.005). In a second treatment group (given Danazol daily after administration of DMBA), only seven of 50 rats (14%) developed palpable mammary carcinoma (p < 0.0005). Danazol therapy resulted in regression of established mammary carcinoma in rats, and produced a striking inhibition of carcinogenesis in those animals treated from the time DMBA was administered. Danazol is clinically safe; studies using it in the treatment of breast cancer in women who are candidates for hormonal ablative therapy seem warranted. Cancer 40:2797‐2800, 1977.